NDA 209803 · Msd Sub Merck
Steglatro
Ertugliflozin · Oral
NovelLast checked: Nov 20, 2026Latest source record: Jun 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Dec 19, 2017
Approved uses
2
Original approval plus efficacy supplements
Registered trials
43
14 Phase 3, 5 recruiting
FAERS reports
1,116
520 serious, 12 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 3, 2026.
STEGLATRO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. STEGLATRO is a sodium glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. ( 1 ) Limitations of Use Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] .
Mechanism: SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Ertugliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, ertugliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 17, 2021 Supplement 4 · Efficacy LabelLetter
- Dec 19, 2017 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
2 products under this application
- STEGLATRO · ERTUGLIFLOZIN 5MG · TABLET, ORAL · Prescription · TE AB
- STEGLATRO · ERTUGLIFLOZIN 15MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Ertugliflozin" as an intervention, any sponsor and status, largest first.
- Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01986881 · 8,246 participants · Start Nov 4, 2013 · Primary completion Dec 27, 2019
Drug: Ertugliflozin; Placebo and 1 more · For: Type 2 Diabetes Mellitus
- Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTEPivotal-lookingCompleted
Matthew Neal MDAcademic, hospital or other
NCT04505774 · 3,591 participants · Start Sep 4, 2020 · Primary completion Aug 31, 2023
Drug: theraputic heparin; prophylactic heparin and 3 more · For: Covid19
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 101 sites in all
- Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01999218 · 1,326 participants · Start Dec 16, 2013 · Primary completion Apr 18, 2017
Drug: Ertugliflozin 5 mg; Ertugliflozin 10 mg and 5 more · For: Type 2 Diabetes Mellitus
- Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02099110 · 1,233 participants · Start Apr 22, 2014 · Primary completion May 26, 2016
Drug: Matching Placebo to Ertugliflozin 5 mg; Matching Placebo to Ertugliflozin 10 mg and 7 more · For: Type 2 Diabetes Mellitus
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic DisordersAcademic, hospital or other
NCT06449235 · 938 participants (planned) · Start Sep 2024 · Primary completion Apr 2025
Drug: Omarigliptin; Sulphonylureas and 7 more · For: Type2diabetes
Sites: Dhaka, Bangladesh
- A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02033889 · 621 participants · Start Dec 13, 2013 · Primary completion Aug 3, 2017
Drug: Ertugliflozin 5 mg; Ertugliflozin 15 mg and 4 more · For: Type 2 Diabetes Mellitus
- A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02630706 · 506 participants · Start Dec 16, 2015 · Primary completion Dec 27, 2017
Drug: Ertugliflozin 5 mg; Ertugliflozin 15 mg and 3 more · For: Type 2 Diabetes Mellitus
- Ertugliflozin's Effect on Heart Function in Diabetic Patients After Myocardial InfarctionPivotal-lookingNot yet recruiting
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT07621380 · 476 participants (planned) · Start Jul 1, 2026 · Primary completion Jan 1, 2028
Drug: Ertugliflozin 10 mg · For: Type 2 Diabetes Mellitus Myocardial Infarction
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea91
- product dose omission issue71
- urinary tract infection66
- vomiting65
- fungal infection58
- no adverse event56
- diabetic ketoacidosis54
- blood glucose increased51
- dizziness49
- diarrhoea47
- drug ineffective41
- product dose omission29
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2017 | 2 |
| 2018 | 132 |
| 2019 | 280 |
| 2020 | 95 |
| 2021 | 81 |
| 2022 | 96 |
| 2023 | 112 |
| 2024 | 116 |
| 2025 | 125 |
| 2026 | 76 |
Recalls
1 FDA enforcement reports for this application.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Steglatro (Ertugliflozin Pidolate)
2024 spending
$16.5M
Beneficiaries
11,118
38,152 claims
Per beneficiary
$1,487
$11.45 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $11,370,498 |
| 2021 | $15,018,152 |
| 2022 | $17,276,294 |
| 2023 | $18,207,799 |
| 2024 | $16,530,191 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Anti-diabetic drugs and weight loss in patients with type 2 diabetes.
Lazzaroni E, Ben Nasr M, Loretelli C, et al. · Pharmacol Res 2021 · Systematic Review
- Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
Kongmalai T, Hadnorntun P, Leelahavarong P, et al. · Front Endocrinol (Lausanne) 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Cannon CP, Pratley R, Dagogo-Jack S, et al. · N Engl J Med 2020 · Equivalence Trial, Multicenter Study
- Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis.
Teng Y, Fan X, Yu R, et al. · BMC Endocr Disord 2024 · Comparative Study, Systematic Review
- Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.
Zhang YS, Zheng YD, Yuan Y, et al. · Front Endocrinol (Lausanne) 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
Hamid AK, Tayem AA, Al-Aish ST, et al. · Ther Adv Cardiovasc Dis 2024 · Systematic Review, Meta-Analysis
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.